MapLight Therapeutics, Inc. Operating Lease Cost
MapLight Therapeutics, Inc. (MPLT) reported Operating Lease Cost of $318.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-13
- MapLight Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $318.00K, a 8.09% decline year-over-year.
- MapLight Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $346.00K, a 0.00% change year-over-year.
- MapLight Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $346.00K, a 1.47% increase year-over-year.
- MapLight Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $346.00K, a 0.86% decline year-over-year.
- MapLight Therapeutics, Inc. operating lease, cost for fiscal 2025 was $1.38M, a 7.04% increase from fiscal 2024.
- MapLight Therapeutics, Inc. operating lease, cost for fiscal 2024 was $1.29M.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $318.00K 10-Q · filed 2026-08-13 | $664.00K 10-Q · filed 2026-08-13 | $1.01M derived: sum of 3 quarters · filed 2026-08-13 | $1.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $346.00K 10-Q · filed 2026-05-14 | $692.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.04M derived: sum of 3 quarters · filed 2026-05-14 | $1.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $346.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $692.00K derived: sum of 2 quarters · filed 2026-03-26 | $1.04M derived: sum of 3 quarters · filed 2026-08-13 | $1.38M 10-K · filed 2026-03-26 |
| 2025-09-30 | $346.00K 10-Q · filed 2025-12-04 | $692.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.04M 10-Q · filed 2025-12-04 | $1.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $346.00K 10-Q · filed 2026-08-13 | $692.00K 10-Q · filed 2026-08-13 | $1.03M derived: sum of 3 quarters · filed 2026-08-13 | $1.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $346.00K 10-Q · filed 2026-05-14 | $687.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.04M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $341.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $690.00K derived: sum of 2 quarters · filed 2026-03-26 | $1.29M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $349.00K 10-Q · filed 2025-12-04 | $951.00K 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |